Skip to content
BiologicalX

Comparison

Rapamycin vs Testosterone

Side-by-side of Rapamycin and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Rapamycin

  • Inhibits mTORC1 signaling by binding FKBP12, reducing protein synthesis and relieving autophagy suppression
  • ITP mouse program reproduced lifespan extension of ~10 to 25% across multiple genetic backgrounds and sexes
  • Mannick trials showed improved influenza vaccine response in elderly adults using analogs of rapamycin
  • PEARL human trial reported acceptable safety at 5 to 10 mg weekly with some functional and lean-mass signals
  • Common dose-limiting adverse effects include stomatitis, acne-like rash, and mildly elevated lipid markers
  • CYP3A4 substrate: grapefruit, ketoconazole, and clarithromycin substantially raise rapamycin exposure

Testosterone

  • Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
  • Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
  • TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
  • Schedule III controlled substance in US; WADA banned in sport
  • Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
  • Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Side-by-side

Attribute Rapamycin Testosterone
Category pharmaceutical hormone
Also known as Sirolimus, Rapamune TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim
Half-life (hr) 62 192
Typical dose (mg) 6 150
Dosing frequency weekly (longevity protocols); daily for transplant indication weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet)
Routes oral intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral
Onset (hr) 1 24
Peak (hr) 2 72
Molecular weight 914.17 288.42
Molecular formula C51H79NO13 C19H28O2
Mechanism Binds FKBP12, and the resulting complex inhibits mTORC1, reducing protein synthesis and autophagy suppression downstream of nutrient and growth-factor signaling. Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects.
Legal status Prescription only (off-label for longevity) Schedule III controlled substance (US); WADA banned
WADA status allowed banned
DEA / Rx Rx only (not a controlled substance) Schedule III
Pregnancy Not recommended Category X; contraindicated in pregnancy (virilizing effect on female fetus)
CAS 53123-88-9 58-22-0
PubChem CID 5284616 6013
Wikidata Q410174 Q150726

Safety profile

Rapamycin

Common side effects

  • mouth ulcers (stomatitis)
  • acne-like rash
  • GI upset
  • altered lipid panel
  • delayed wound healing

Contraindications

  • active infection
  • severe hepatic impairment
  • planned surgery (delayed wound healing)
  • pregnancy
  • live vaccines within dosing window

Interactions

  • strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit): substantially raises rapamycin levels, toxicity risk(major)
  • strong CYP3A4 inducers (rifampin, St John's wort): lowers rapamycin levels, reduced effect(major)
  • ACE inhibitors: increased risk of angioedema(moderate)
  • live vaccines: reduced vaccine efficacy due to immunosuppression(major)

Testosterone

Common side effects

  • erythrocytosis
  • acne
  • oily skin
  • fluid retention
  • increased body hair
  • fertility suppression
  • injection-site reactions

Contraindications

  • active prostate cancer
  • active breast cancer
  • untreated severe sleep apnea
  • untreated severe BPH
  • uncontrolled heart failure
  • polycythemia at baseline

Interactions

  • warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
  • insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
  • 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
  • aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)

Which Should You Take?

Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Rapamycin is the right call when one of the conditionals below applies.

  • If your priority is healthspan extension, pick Rapamycin.
  • If your priority is immune support, pick Rapamycin.
  • If your priority is hormonal optimization, pick Testosterone.
  • If your priority is sexual function, pick Testosterone.

Edge case: Testosterone is contraindicated in pregnancy; Rapamycin is the safer pick if that applies.

Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Rapamycin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Rapamycin and Testosterone?

Rapamycin and Testosterone differ in category (pharmaceutical vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Rapamycin or Testosterone?

Rapamycin half-life is 62 hours; Testosterone half-life is 192 hours.

Can you stack Rapamycin with Testosterone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper